Home / Intelligence / Webinars / Elevating Commercialization in China Part 2: The Key to Pricing and Access Optimization
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.
Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to elevate commercial success in China.
Key Webinar Topics
- Latest trends on the pricing and market access landscape in China
- What access pathways/programs are available for innovative products
- Insights from recent launches
Featuring
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Allen Liu
Senior Consultant & APAC Expert,
Strategic Advisory
Yitong Li
Senior Consultant & APAC Expert,
Strategic Advisory
In Part 3 of this webinar series, our experts will explore:
Part 3: The Winning Commercial Model | Upcoming
Building a model to match China’s changing dynamics
Complete the form below to view the on-demand webinar
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Rise with the waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future
Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]
Read More
Webinars
2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]
Sign Up Now
Blog
Rise with the waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access
Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, […]
Read More